TLDR:
- iRhythm receives FDA 510(k) clearance for Zio AT device updates
- Stock surges over 16% on the news
- First of two pending 510(k) clearances following FDA warning letter
- Device monitors heart activity continuously for up to 14 days
- Company aims to resolve regulatory issues dating back to 2022
iRhythm Technologies (NASDAQ: IRTC) saw its shares soar more than 16% in trading Tuesday after announcing FDA clearance for design modifications to its Zio AT cardiac monitoring device.
The approval marks a significant milestone in the company’s efforts to address ongoing regulatory challenges.
The clearance follows a 510(k) submission for design modifications that were previously filed under a “letter to file” procedure. This represents the first of two pending 510(k) clearances the company is seeking as part of its regulatory compliance efforts. The Zio AT device, which remains commercially available in the United States, combines a wearable ECG patch with advanced AI-powered software for comprehensive cardiac monitoring.
The regulatory approval comes at a crucial time for iRhythm, which has been working to resolve issues raised in an FDA warning letter from May 2024. The warning letter, issued after an inspection of the company’s Cypress, California facility, cited violations of the Federal Food, Drug, and Cosmetic Act, including labeling issues, quality system problems, and delays in reporting adverse events, particularly concerning two patient deaths.
Quentin Blackford, iRhythm’s President and CEO, expressed satisfaction with the development, stating,
“This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a priority for our teams to demonstrate iRhythm’s commitment to quality, compliance and performance.”
The Zio AT system consists of three key components: the Zio AT patch, which continuously records ECG data for up to 14 days; a wireless gateway that connects the patch to the company’s software platform; and ZEUS, iRhythm’s deep-learning algorithm that analyzes transmitted cardiac events. The device is designed for non-critical care patients aged 18 and older who may experience various cardiac symptoms or be asymptomatic.
The system’s clinical effectiveness has been well-documented, with over 100 original scientific research manuscripts supporting its value. The company reports a 98% patient compliance rate, attributed to the device’s user-friendly design that requires no patient manipulation. Physicians have shown strong confidence in the system, agreeing with the comprehensive end-of-wear report 99% of the time.
Financial analysts have responded positively to the news. Truist Securities raised their price target for iRhythm shares from $80 to $95, based on a valuation of approximately 4.5x EV/Sales against estimated 2025 revenue of $694 million. The increase reflects growing confidence in the company’s ability to resolve its regulatory challenges.
Oppenheimer analysts note that while one 510(k) clearance has been secured, uncertainty remains regarding the timing of the second clearance. They suggest that the subsequent ZM2 submission might be delayed until 2025.
However, they also highlight significant market potential, indicating that capturing just 10% of the Mobile Cardiac Telemetry (MCT) market could generate an additional $100 million in revenue for iRhythm, in a space currently dominated by competitors like Boston Scientific and Philips Healthcare.
The company recently expanded its global presence, securing Japanese regulatory approval for the Zio AT system last month. This international expansion, combined with the latest FDA clearance, positions iRhythm to potentially capture a larger share of the growing cardiac monitoring market.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support